Article · Wikipedia archive · Last revised Jul 6, 2026

Propylallyltryptamine

Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT). The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor. It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). The chemical synthesis of PALT has been described. A notable analogue of PALT is iPALT (ASR-3003). PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.

Last revised
Jul 6, 2026
Read time
≈ 1 min
Length
154 w
Citations
7
Source
Wikipedia ↗
Propylallyltryptamine
Clinical data
Other namesPALT; N-Propyl-N-allyltryptamine; ASR-3004; ASR3004
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • N-[2-(1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-1-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC16H22N2
Molar mass242.366 g·mol−1
3D model (JSmol)
  • CCCN(CCC1=CNC2=CC=CC=C21)CC=C
  • InChI=1S/C16H22N2/c1-3-10-18(11-4-2)12-9-14-13-17-16-8-6-5-7-15(14)16/h3,5-8,13,17H,1,4,9-12H2,2H3
  • Key:BPHDZENPKNMIRD-UHFFFAOYSA-N

Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family.1 It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT).1 The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor.1 It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).1 The chemical synthesis of PALT has been described.1 A notable analogue of PALT is iPALT (ASR-3003).1 PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.1

See also

See also

References

References

  1. US 20240277665A1, Daley PF, Cozzi NV, Callaway WB, "Asymmetric allyl tryptamines", issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc.